- t2cure’s cell therapy is available through cooperating clinical centres
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
Use of t2c001 in peripheral diseases
Posted below are scientific articles about t2c001 in peripheral artery diseases and about the indication thromboangiitis obliterans:
Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schlüter M, Tonn T, Seeger F, Dimmeler S, Lindhoff-Last E, Zeiher AM: Intraarterial Administration of Bone Marrow Mononuclear Cells in Patients With Critical Limb Ischemia. A Randomized-Start, Placebo-Controlled Pilot Trial (PROVASA). Circ Cardiovasc Interv. 2011. 4(1): 26-37.
Fadini GP, Agostini C, Avogaro A: Autologous stem cell therapy for peripheral arterial disease. Meta-analysis and systematic review of literature. Atherosclerosis. 2010 Mar;209(1):10-7
Arkkila P: Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis. 2006 Apr 27;1:14.
Olin JW: Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol. 2006 Jan;18(1):18-24.